|
Summary of Contents
SECTOR
UPDATE
Information Technology
Rupee plays spoilsport
The sharp appreciation of the rupee against all the other major currencies in the past couple of weeks has dented the sentiments towards the tech stocks and rightly so. That's because the unexpected sharp appreciation in the rupee at the end of the quarter would not only adversely affect the fourth quarter's financial performance of the information technology (IT) companies but also have a strong influence on their annual growth guidance for FY2008.
VIEWPOINT
Matrix Laboratories
Mylan's exclusivity for Norvasc to benefit Matrix
Mylan, the US-based generic company, has been awarded 180-day exclusivity to market Amlodipine Besylate, the generic version of Pfizer's anti-hypertensive, Norvasc. India's Matrix Laboratories, in which Mylan had acquired a controlling interest in 2006, is the supplier of active pharmaceutical ingredients (APIs) to Mylan.
|
